PDL BioPharma (FRA:PDL) 3-Year EBITDA Growth Rate : 0.00% (As of Jun. 2020)

View and export this data going back to 2006. Start your Free Trial

What is PDL BioPharma 3-Year EBITDA Growth Rate?

PDL BioPharma's EBITDA per Share for the three months ended in Jun. 2020 was €-0.10.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Competitive Comparison of PDL BioPharma's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, PDL BioPharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PDL BioPharma's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDL BioPharma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where PDL BioPharma's 3-Year EBITDA Growth Rate falls into.

PDL BioPharma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

PDL BioPharma (FRA:PDL) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

PDL BioPharma 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

PDL BioPharma (FRA:PDL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (FRA:PDL) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

932 Southwood Boulevard, Incline Villiage, NV, USA, 89451

Website

http://www.pdl.com

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.

PDL BioPharma (FRA:PDL) Headlines

No Headlines